MR1‐dependent immune surveillance of the skin contributes to pathogenesis and is a photobiological target of UV light therapy in a mouse model of atopic dermatitis.

Allergy ◽  
2021 ◽  
Author(s):  
Karmella Naidoo ◽  
Katherine Woods ◽  
Christophe Pellefigues ◽  
Alissa Cait ◽  
David O’Sullivan ◽  
...  
2001 ◽  
Vol 107 (2) ◽  
pp. 359-366 ◽  
Author(s):  
Amy L. Woodward ◽  
Jonathan M. Spergel ◽  
Harri Alenius ◽  
Emiko Mizoguchi ◽  
Atul K. Bhan ◽  
...  

2021 ◽  
Author(s):  
Natalija Novak ◽  
Heike Weighardt ◽  
Rafael Valdelvira ◽  
Elena Izquierdo ◽  
Irmgard Förster ◽  
...  

2005 ◽  
Vol 11 (3) ◽  
pp. 209-217 ◽  
Author(s):  
Katsuo Matsumoto ◽  
Koji Mizukoshi ◽  
Midori Oyobikawa ◽  
Hiroshi Ohshima ◽  
Yuji Sakai ◽  
...  

2020 ◽  
Vol 37 (2) ◽  
pp. 123-127
Author(s):  
Kyeong Ju Park ◽  
Ho-Sueb Song

Background: This study was designed using a mouse model of atopic dermatitis [phthalic anhydride (PA)-treated mice], to investigate the anti-inflammatory effect of bee venom pharmacopuncture (BVP) in keratinocytes.Methods: Western blot analysis was performed to investigate inflammation related protein expression of iNOS, COX-2, phospho-ERK (p-ERK), and ERK, in LPS (1 μg/mL)-activated keratinocytes, following BVP treatment, and in PA-treated mice, after BVP treatment. Griess reaction was performed to investigate NO concentration. Enzyme-linked immunosorbent assays were used to determine the concentrations of interleukin (IL)-4+, IL-17A+, IL-13 and IL-4 in PA-treated mice after BVP treatment. In addition, monocyte, macrophage, neutrophil, and eosinophil counts were measured to observe the changes in white blood cell infiltration.Results: The keratinocytes of the BVP-treated group showed a decreased expression of iNOS, COX-2, ERK at 5 OX-2, ERK E, and p-ERK at 1, 2 and 5 RKRK ERK ERK, and a dose-dependent decrease in NO concentration at 2 and 5 ntrationof s. In the BVP-treated groups (0.1 μ.1-trea μ.1-treated gr), PA-treated mice showed recovery after 4 weeks which was dose-dependent, showing a significant decrease in clinical scores for AD, and a decreased concentration of IL-13 and IL-4 with BV treatment. There was a dose-dependent decrease in the infiltration of eosinophils, neutrophils, monocytes, macrophages, and a decreased thickness of the epidermis due to inflammation, and decreased expressions of iNOS, COX-2, p-ERK, ERK, especially in the 0.1 μ0/mL BVP-treated group,<br>Conclusion: These results suggest that BVP may be an effective alternative treatment for atopic dermatitis.


PLoS ONE ◽  
2015 ◽  
Vol 10 (8) ◽  
pp. e0135070 ◽  
Author(s):  
Nadezda Shershakova ◽  
Elena Bashkatova ◽  
Alexander Babakhin ◽  
Sergey Andreev ◽  
Alexandra Nikonova ◽  
...  

Allergy ◽  
2018 ◽  
Vol 73 (9) ◽  
pp. 1801-1811 ◽  
Author(s):  
J. U. Shin ◽  
S. H. Kim ◽  
J. Y. Noh ◽  
J. H. Kim ◽  
H. R. Kim ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 763 ◽  
Author(s):  
Takato Suzuki ◽  
Kyoko Nishiyama ◽  
Koji Kawata ◽  
Kotaro Sugimoto ◽  
Masato Isome ◽  
...  

Some lactic acid bacteria (LAB) are known to improve atopic dermatitis (AD) through the regulation and stimulation of the host immune system. In this study, we found that ingestion of yogurt containing Lactococcus lactis 11/19-B1 strain (L. lactis 11/19-B1) daily for 8 weeks significantly improved the severity scoring of atopic dermatitis (SCORAD) system score from 38.8 ± 14.4 to 24.2 ± 12.0 in children suffering from AD. We tried to identify which LAB species among the five species contained in the test yogurt contributed to the improvement in AD pathology using an AD mouse model induced by repeated application of 1-fluoro-2, 4-dinitrobenzene (DNFB). AD-like skin lesions on the dorsal skin and ear were most improved by L. lactis 11/19-B1 intake among the five LAB species. In addition, analysis of CD4+ T cell subsets in Peyer’s patches (PPs) and cervical lymph nodes (CLNs) indicated that the intake of L. lactis 11/19-B1 generally suppressed all subsets related to inflammation, i.e., Th1, Th2 and Th17, instead of activating the suppressive system, Treg, in the AD mouse model. Histological observations showed ingestion of L. lactis 11/19-B1 significantly suppressed severe inflammatory findings, such as inflammatory cell filtration, epidermal erosion and eosinophil infiltration. These results suggest that the immunomodulatory effects of L. lactis 11/19-B1 contribute to improvements in AD pathology.


Sign in / Sign up

Export Citation Format

Share Document